

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – March 8, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 8, 2017 DUR Minutes – Vote
- B. February 8, 2017 DUR Recommendations Memorandum

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/FDA Safety Alerts
– See Appendix B**

- A. Medication Coverage Activity for February 2017
- B. Pharmacy Help Desk Activity for February 2017
- C. FDA Safety Alerts

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Nuplazid™ (Pimavanserin) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Veltassa® (Patiromer) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Kanuma® (Sebelipase Alfa) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Picato® (Ingenol Mebutate 0.015% and 0.05% Gel)
– See Appendix F**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Onzetra® Xsail® (Sumatriptan Nasal Powder) and
Zembrace™ SymTouch™ (Sumatriptan Injection) – See Appendix G**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Briviact® (Brivaracetam), Fycompa™ (Perampanel Oral Suspension), and Carnexiv™ (Carbamazepine Injection) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

11. 30-Day Notice to Prior Authorize Spinraza™ (Nusinersen) – See Appendix I

- A. Spinal Muscular Atrophy
- B. Market News and Updates
- C. Spinraza™ (Nusinersen) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

12. Annual Review of Pulmonary Hypertension Medications – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Pulmonary Hypertension Medications
- C. Prior Authorization of Pulmonary Hypertension Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Pulmonary Hypertension Medications

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

13. Annual Review of Multiple Sclerosis Medications and 30-Day Notice to Prior Authorize Zinbryta™ (Daclizumab) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Multiple Sclerosis Medications
- C. Prior Authorization of Multiple Sclerosis Medications
- D. Market News and Updates
- E. Zinbryta™ (Daclizumab) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Multiple Sclerosis Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. Annual Review of Makena® and Vaginal Progesterone Products and 30-Day Notice to Prior Authorize Hydroxyprogesterone Caproate Injection – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Makena® and Vaginal Progesterone Products
- C. Prior Authorization of Makena® and Vaginal Progesterone Products
- D. Market News and Updates
- E. Hydroxyprogesterone Caproate Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Makena® and Vaginal Progesterone Products

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

15. Annual Review of Naloxone Medications – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Naloxone Medications
- C. Prior Authorization of Naloxone Medications
- D. Naloxone Statistics and Trends
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Naloxone Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. 30-Day Notice to Prior Authorize Zinplava™ (Bezlotoxumab) – See Appendix N

- A. Introduction
- B. Zinplava™ (Bezlotoxumab) Product Summary

C. College of Pharmacy Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

17. FDA and DEA Updates – See Appendix O

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

- A. Diabetic Medications
- B. Antihypertensive Medications
- C. Granulocyte-Colony Stimulating Factors (G-CSFs)
- D. Osteoporosis Medications
- E. Strensiq® (Asfotase Alfa)
- F. Hemophilia Medications
- G. Idiopathic Pulmonary Fibrosis Medications
- H. Alpha₁-Proteinase Inhibitors

**Future business subject to change.*

19. Adjournment